Milan J. Anadkat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Milan J. Anadkat has a total of 508 co-authors. Here are the top co-authors by number of shared publications:
- Anisha B. Patel
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX
4 shared publications - Antoni Ribas
Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, USA
4 shared publications - Egmidio Medina
University of California Los Angeles 1 Department of Molecular and Medical Pharmacology Los Angeles, California
4 shared publications Einat Shacham-Shmueli
4 shared publicationsGalit Zelinger
4 shared publications- Mario E. Lacouture
NYU Grossman Long Island School of Medicine NYU Langone Hospital Minneola New York USA
4 shared publications
Latest Publications
- Open Access
- 13 October 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (2) , 254-263
Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial
Background: The results of a previous phase IIa trial suggested efficacy of the anti-C5a compound vilobelimab in a small number of patients with severe hidradenitis suppurativa (HS) refractory to adalimumab treatment. Objectives: To study the efficacy of vilobelimab in a larger-scale randomized phase IIb trial (SHINE) of patients with moderate-to-severe HS. Methods: In total, 177 patients with moderate-to-severe HS were treated either with placebo or one of four doses of vilobelimab, a monoclonal antibody that targets the complement split product C5a. Hidradenitis Suppurativa Clinical Response (HiSCR) at 16 weeks was the primary endpoint. Those who achieved HiSCR switched to open-label low-dose vilobelimab; those who did not were switched to medium-dose vilobelimab. The trial was registered with the EU Clinical Trials Register (EudraCT number 2017-004501-40) and ClinicalTrials.gov (NCT03487276). Results: The study did not meet the primary endpoint, perhaps due, in part, to an unexpectedly high HiSCR placebo response rate of 47.1%. HS flares decreased and post hoc analysis showed that high-dose vilobelimab significantly decreased the median draining tunnel counts and IHS4 score by 63%. Following the switch to medium-dose vilobelimab at week 16, 45.5% of those who did not respond to treatment achieved HiSCR at week 40. Conclusions: Compared with placebo, vilobelimab treatment did not result in significant HiSCR improvements in patients with moderate-to-severe HS. Post hoc analysis revealed significant effects for the highest tested dose on draining tunnel reduction and IHS4 score, which captures reductions in draining tunnels. These findings warrant further investigation.
- 13 October 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (2) , 254-263
Open AccessVilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial
Background: The results of a previous phase IIa trial suggested efficacy of the anti-C5a compound vilobelimab in a small number of patients with severe hidradenitis suppurativa (HS) refractory to adalimumab treatment. Objectives: To study the efficacy of vilobelimab in a larger-scale randomized phase IIb trial (SHINE) of patients with moderate-to-severe HS. Methods: In total, 177 patients with moderate-to-severe HS were treated either with placebo or one of four doses of vilobelimab, a monoclonal antibody that targets the complement split product C5a. Hidradenitis Suppurativa Clinical Response (HiSCR) at 16 weeks was the primary endpoint. Those who achieved HiSCR switched to open-label low-dose vilobelimab; those who did not were switched to medium-dose vilobelimab. The trial was registered with the EU Clinical Trials Register (EudraCT number 2017-004501-40) and ClinicalTrials.gov (NCT03487276). Results: The study did not meet the primary endpoint, perhaps due, in part, to an unexpectedly high HiSCR placebo response rate of 47.1%. HS flares decreased and post hoc analysis showed that high-dose vilobelimab significantly decreased the median draining tunnel counts and IHS4 score by 63%. Following the switch to medium-dose vilobelimab at week 16, 45.5% of those who did not respond to treatment achieved HiSCR at week 40. Conclusions: Compared with placebo, vilobelimab treatment did not result in significant HiSCR improvements in patients with moderate-to-severe HS. Post hoc analysis revealed significant effects for the highest tested dose on draining tunnel reduction and IHS4 score, which captures reductions in draining tunnels. These findings warrant further investigation.
- Open Access
- 5 April 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (6) , 1587-1594
Correction: Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions
- 5 April 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (6) , 1587-1594
Open AccessCorrection: Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions
- Open Access
- 20 February 2025
- Published by Taylor & Francis in Video Journal of Biomedicine
- Vol. 7 (1) , 1-3
Spesolimab Treatment for the Prevention of Flares in People with Generalized Pustular Psoriasis (GPP): A Video Summary of the EFFISAYIL® 2 Study
Prof. Morita presents the EFFISAYIL® 2 clinical trial, which investigated spesolimab treatment for the prevention of GPP flares.
- 20 February 2025
- Published by Taylor & Francis in Video Journal of Biomedicine
- Vol. 7 (1) , 1-3
Open AccessSpesolimab Treatment for the Prevention of Flares in People with Generalized Pustular Psoriasis (GPP): A Video Summary of the EFFISAYIL® 2 Study
Prof. Morita presents the EFFISAYIL® 2 clinical trial, which investigated spesolimab treatment for the prevention of GPP flares.
- Open Access
- 10 February 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (2) , 395-411
Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions
Introduction Spesolimab, a selective, humanised monoclonal antibody targeting the interleukin-36 receptor, is approved for the treatment of generalised pustular psoriasis (GPP). As a result of the limited patient numbers in GPP trials of spesolimab, analysing safety events across dermatological and non-dermatological diseases helps to further characterise the known safety profile of spesolimab. Here, we analyse predefined safety events from nine randomised, placebo-controlled spesolimab trials across dermatological (including GPP) and gastrointestinal conditions. Methods Predefined safety events were based on the known safety profile of spesolimab across all diseases investigated to date and potential risks of biological therapeutics, and included serious/severe/opportunistic infections, hypersensitivity, malignancies and peripheral neuropathy. Results Including placebo-controlled trials and open-label periods/trials, 589 patients received ≥ 1 dose of spesolimab (772.2 patient-years; mean exposure 1.31 patient-years). Overall, 452 patients had long-term exposure (≥ 6 months) to spesolimab, with 31 patients up to ≥ 3 years. In placebo-controlled periods, 445 patients had exposure to spesolimab (162.0 patient-years; mean exposure 0.36 patient-years). Severe/serious/opportunistic infections occurred in 0–3.2% of spesolimab-treated patients and 0–14.3% of placebo-treated patients. Malignancies occurred infrequently across trials (0–6.7% in spesolimab, 0–2.3% in placebo). Peripheral neuropathy events also occurred infrequently, with single events reported in the placebo arm of EFFISAYIL® 2, and the spesolimab and placebo arms of palmoplantar pustulosis Study 2. Potential hypersensitivity events occurred in all trials, except for Crohn’s disease, and were largely balanced between spesolimab (7.7–33.3%) and placebo (4.3–44.4%). Conclusions Across placebo-controlled periods of spesolimab trials in dermatological and non-dermatological conditions, severe/serious/opportunistic infections, malignancies and peripheral neuropathy events were low, with no evidence for an increased risk with spesolimab versus placebo. Potential hypersensitivity events were similar between spesolimab and placebo. These results support the favourable safety profile of spesolimab observed in EFFISAYIL® 2, the largest GPP trial conducted to date. Graphical Abstract
- 10 February 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (2) , 395-411
Open AccessAnalysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions
Introduction Spesolimab, a selective, humanised monoclonal antibody targeting the interleukin-36 receptor, is approved for the treatment of generalised pustular psoriasis (GPP). As a result of the limited patient numbers in GPP trials of spesolimab, analysing safety events across dermatological and non-dermatological diseases helps to further characterise the known safety profile of spesolimab. Here, we analyse predefined safety events from nine randomised, placebo-controlled spesolimab trials across dermatological (including GPP) and gastrointestinal conditions. Methods Predefined safety events were based on the known safety profile of spesolimab across all diseases investigated to date and potential risks of biological therapeutics, and included serious/severe/opportunistic infections, hypersensitivity, malignancies and peripheral neuropathy. Results Including placebo-controlled trials and open-label periods/trials, 589 patients received ≥ 1 dose of spesolimab (772.2 patient-years; mean exposure 1.31 patient-years). Overall, 452 patients had long-term exposure (≥ 6 months) to spesolimab, with 31 patients up to ≥ 3 years. In placebo-controlled periods, 445 patients had exposure to spesolimab (162.0 patient-years; mean exposure 0.36 patient-years). Severe/serious/opportunistic infections occurred in 0–3.2% of spesolimab-treated patients and 0–14.3% of placebo-treated patients. Malignancies occurred infrequently across trials (0–6.7% in spesolimab, 0–2.3% in placebo). Peripheral neuropathy events also occurred infrequently, with single events reported in the placebo arm of EFFISAYIL® 2, and the spesolimab and placebo arms of palmoplantar pustulosis Study 2. Potential hypersensitivity events occurred in all trials, except for Crohn’s disease, and were largely balanced between spesolimab (7.7–33.3%) and placebo (4.3–44.4%). Conclusions Across placebo-controlled periods of spesolimab trials in dermatological and non-dermatological conditions, severe/serious/opportunistic infections, malignancies and peripheral neuropathy events were low, with no evidence for an increased risk with spesolimab versus placebo. Potential hypersensitivity events were similar between spesolimab and placebo. These results support the favourable safety profile of spesolimab observed in EFFISAYIL® 2, the largest GPP trial conducted to date. Graphical Abstract
- 5 October 2023
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 90 (2) , 388-390
Risk of keratinocyte carcinomas following extracorporeal photopheresis among lung transplant recipients: A retrospective cohort study
- 5 October 2023
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 90 (2) , 388-390
Risk of keratinocyte carcinomas following extracorporeal photopheresis among lung transplant recipients: A retrospective cohort study
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables and Figure Legends from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
Supplementary Tables and Figure Legends
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables and Figure Legends from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
Supplementary Tables and Figure Legends
- Open Access
- 1 January 2020
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 26 (6)
Pemphigus foliaceus in a patient with gastrointestinal stromal tumor treated with adjuvant imatinib mesylate
Pemphigus is an autoimmune bullous disease with a number of described associations, including medications, which have been grouped into three structural categories - thiol drugs, phenol drugs, and drugs with neither functional group [1]. Discontinuation of the offending medication is considered a mainstay of therapy. We report a patient in whom the onset of pemphigus foliaceus was associated with initiation of imatinib mesylate adjuvant therapy in a patient with resected gastrointestinal stromal tumor (GIST). Imatinib was continued because of the survival benefit to the patient with a resected, high risk GIST. Treatment with rituximab resulted in near resolution of his blistering rash and follow up enzyme-linked immunosorbent assay (ELISA) demonstrated reference range immunoreactivity for both desmoglein 1 and desmoglein 3. After dose increase of imatinib therapy owing to tumor growth, the patient subsequently again developed a similar eruption. Re-biopsy and ELISA were consistent with recurrence of pemphigus. In conclusion, although the patient's pemphigus was cleared with a single cycle of rituximab infusions while continuing imatinib therapy, the disease returned after imatinib dose was increased a year later, suggesting a dose-response relationship.
- 1 January 2020
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 26 (6)
Open AccessPemphigus foliaceus in a patient with gastrointestinal stromal tumor treated with adjuvant imatinib mesylate
Pemphigus is an autoimmune bullous disease with a number of described associations, including medications, which have been grouped into three structural categories - thiol drugs, phenol drugs, and drugs with neither functional group [1]. Discontinuation of the offending medication is considered a mainstay of therapy. We report a patient in whom the onset of pemphigus foliaceus was associated with initiation of imatinib mesylate adjuvant therapy in a patient with resected gastrointestinal stromal tumor (GIST). Imatinib was continued because of the survival benefit to the patient with a resected, high risk GIST. Treatment with rituximab resulted in near resolution of his blistering rash and follow up enzyme-linked immunosorbent assay (ELISA) demonstrated reference range immunoreactivity for both desmoglein 1 and desmoglein 3. After dose increase of imatinib therapy owing to tumor growth, the patient subsequently again developed a similar eruption. Re-biopsy and ELISA were consistent with recurrence of pemphigus. In conclusion, although the patient's pemphigus was cleared with a single cycle of rituximab infusions while continuing imatinib therapy, the disease returned after imatinib dose was increased a year later, suggesting a dose-response relationship.